Anju Ghangurde
Executive Editor at Scrip
Executive Editor at The Pink Sheet
Executive Editor (Asia Pacific), Scrip/Pink Sheet, @Citeline @NorstellaCo but views own; believe in karma & that moms can move mountains
Articles
-
6 days ago |
insights.citeline.com | Lisa Takagi |Joseph Haas |Anju Ghangurde |Vibha Ravi
Asia Deal Watch: Daiichi Taps Into Wayfinder’s RNA-Encoding PlatformPlus deals involving Elix/PRISM, Rege/Syros, Kaken/KalVista, Dr. Reddy’s/Aurigene/Edity, Nissan Chemical/Sanwa, Lupin/Renascience, Shionogi/Link Medicine, Abbisko/Merck & Co., Ono/Reborna and Apollomics/LaunXp.
-
1 week ago |
insights.citeline.com | Anju Ghangurde
India Signals “Systemic Changes” In CGT Regulatory Approach India is pressing ahead with “big shifts” in its regulatory approach for cell and gene therapies. Reduced “layers of review”, tighter internal timelines, upcoming guidelines to facilitate CGT development and reforms in the constitution of subject expert committees are some of the key changes. Big shifts in India's CGT regulatory approach (Shutterstock)
-
1 week ago |
insights.citeline.com | Anju Ghangurde
US Tariffs And Manufacturing Concentration: Double-Edged Sword? India and the US are the leading manufacturers of finished dosages for the US market in terms of volume, though the US relies heavily on India for solid oral dosage forms and specific generics, including lenalidomide and albuterol. Scrip talks to experts on some of the key implications of geographic concentration of production for the US market amid the specter of tariffs. Manufacturing concentration and the tariff option
-
2 weeks ago |
insights.citeline.com | Anju Ghangurde
Vocal For ‘Glocal’: How Menarini Is Adapting To Outperform In The Asia Pacific Menarini's Asia-Pacific CEO talks to Scrip about how the Italian group is tailoring its portfolio and pricing approach to local markets making strong strides in primary care and consumer health, while also charting a distinct path in rare diseases and oncology. The China market is also a key focus including as a potential source of innovation as is partnering, where the group has a rich history.
-
3 weeks ago |
insights.citeline.com | Anju Ghangurde
How Big Pharma Is Redefining, Scaling India GCCs Amid Tech AdvancesSenior executives from AstraZeneca, BMS, Novo Nordisk, Takeda and Regeneron outline how big pharma's global capability centers (GCCs) in India are evolving beyond cost efficiency, focusing on innovation, “agile experimentation” and new technology including GenAI, virtual & augmented reality, with some positioned as COEs. Will Indian multinationals use the GCC approach?
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 1K
- Tweets
- 9K
- DMs Open
- Yes
Tense moments but it’s come home … in style & with some calm from KL Rahul towards the end …….Heartiest congratulations Team India
India are champion of champions 🏆🏆🏆 #ChampionsTrophy2025 #INDvsNZ https://t.co/LG7ZIyXFx5
Tariff baby #tariff…what India pharma CEOs said on that & shape of mfg networks. 42%Rx filled by US residents were supplied by Indian firms in 2022 … tariffs rational? Wait & watch it is
India Pharma Chiefs On Future Manufacturing Networks And Specter Of Tariffs https://t.co/BzLSVlPxIp #PharmaScrip https://t.co/ElO0jOUDnm
RT @ScripJungWon: https://t.co/Fp1nAKvhni